The combined inhibition of the lysine methyltransferases SMYD2-EZH2 and the RTK c-MET is a novel molecular mechanism, making the EVOO phenolics, represented by OC, exceptionally unique anti-CRC nutraceuticals, useful for both CRC patients and survivors. This evidence concerns the gene SMYD2 and colorectal carcinoma.